Despite decades of research, there is no scientific consensus method for representing the menstrual cycle as a continuous timeline. Common phase- and count-based methods oversimplify hormonal dynamics and overlook individual variability in ovulation timing, reducing statistical power and misaligning trajectories. To address this, we introduce Phase-Aligned Cycle Time Scaling (PACTS) and its companion R package, `menstrualcycleR`, which generates continuous time variables anchored to both menses and ovulation, improving alignment of hormonal dynamics across individuals and cycles in an accessible, reproducible way. This approach accommodates variable cycle lengths and supports various ovulation detection methods or norm-based ovulation estimation when biomarkers are unavailable. Using daily urinary hormone data from 44 cycles, we show that PACTS improves alignment and estimation of estradiol (E2) and progesterone (P4) trajectories compared to traditional methods. This has implications for improved cycle effect estimation both within samples and across studies. The variables produced by PACTS also support hierarchical nonlinear models, such as generalized additive mixed models, for high-resolution analysis of cyclical outcomes and quantification of related effect sizes. Since a variety of clinical disorders are currently diagnosed using cycle count methods, future directions should consider how this approach may improve diagnostic accuracy (e.g., in premenstrual dysphoric disorder (PMDD), catamenial epilepsy, or menstrual migraine). Together, PACTS and `menstrualcycleR` offer a reproducible framework that improves precision and interpretability in menstrual cycle research.
20 January 2023 in Alcohol, Clinical and Experimental Research
Background: Females who misuse alcohol experience high rates of negative physical and mental health consequences. Existing findings are inconsistent but suggest a relationship between ovarian hormones and alcohol use. We aim to clarify how alcohol use and drinking motives vary across the menstrual cycle in female psychiatric outpatients using the luteinizing hormone (LH)‐confirmed cycle phase.Methods: Daily self‐reports (n = 3721) were collected from 94 naturally cycling females, recruited for past‐month suicidal ideation, during the baseline phase of three parent clinical trials between February 2017 and May 2022. Multilevel logistic and linear models estimated the relationship between the cycle phase (with LH‐surge confirmed ovulation) and daily alcohol use or drinking motives, moderated by the weekend. Models were adjusted for age, legal drinking status, substance use disorder, and the COVID‐19 pandemic, and included random effects.Results: Participants were generally more likely to drink in the midluteal (vs. perimenstrual) phase, but more likely to drink heavily on weekends in periovulatory and perimenstrual (vs. midluteal) phases. Social motives for drinking were significantly higher on weekends in the periovulatory, mid‐follicular, and midluteal phases (vs. weekdays), but this finding was non‐significant in the perimenstrual phase. Participants rated drinking to cope higher in the perimenstrual phase (vs. midluteal phase), regardless of the weekend.Conclusion: In a psychiatric sample with LH‐surge‐confirmed ovulation, we find an increased likelihood to drink heavily in periovulatory and perimenstrual phases on weekends. We also find that the perimenstrual phase is associated with increased drinking to cope, and relatively lower weekend social drinking. Finally, random effects across models suggest individual differences in the extent to which the cycle influences drinking. Our findings stress (1) predictable phases of increased high‐risk alcohol use across the menstrual cycle, and (2) the importance of individual assessment of cyclical changes in alcohol use to predict and prevent ovulation‐ and menses‐related surges in heavy drinking.
Accumulating evidence indicates that most female patients with suicidal ideation (SI) experience a dimensional worsening of depressive symptoms and SI in the perimenstrual phase of the menstrual cycle. Experimental trials demonstrate that acute perimenstrual administration of estradiol (E2; with or without progesterone/P4), can prevent these recurring episodes of increased risk. In this archival sample drawn from one of these clinical trials, we examined whether these beneficial E2 effects extend to specific types of cognition. For a double-blind, placebo-controlled experiment, we recruited transdiagnostic psychiatric outpatients with natural menstrual cycles who experienced past-month SI (N(per-protocol sample)=23; N(intent-to-treat sample)=44). In each of two counterbalanced conditions (perimenstrual administration of 0.1mg/d transdermal E2 vs. placebo), participants completed three cognitive tasks in three menstrual cycle phases (mid-luteal, perimenstrual, mid-follicular). Multilevel models revealed a significant interaction of condition and phase: E2 administration prevented mid-luteal-to-perimenstrual drops in working memory (p=.006) and verbal fluency (p=.005) observed under placebo. No effects were found for inhibitory control. In conclusion, we find perimenstrual declines in working memory and verbal fluency in patients with SI, which can be prevented by administering E2. This study contributes to our understanding of the hormone-brain pathways involved in the cyclical worsening of suicidality.